| Domain | Key annotations | Suggested ontology terms | Evidence |
|---|---|---|---|
| Identity / identifiers | **Craniofacial microsomia (CFM)** is a **congenital** disorder/spectrum characterized by unilateral or bilateral underdevelopment of structures derived largely from the **first and second pharyngeal arches**; commonly overlaps conceptually with **hemifacial microsomia**, **oculoauriculovertebral spectrum (OAVS)**, and sometimes **Goldenhar spectrum** in clinical literature. Disease-level information here is derived primarily from **aggregated cohort studies, disease resources, and research cohorts**, not EHR-only sources. **MONDO:** MONDO:0015397 (craniofacial microsomia). | MONDO:0015397; UBERON: pharyngeal arch; UBERON: mandible; UBERON: external ear | (pqac-00000003, pqac-00000014, pqac-00000022) |
| Core phenotype | Typical manifestations include **facial asymmetry**, **mandibular hypoplasia**, **microtia/ear dysplasia**, **preauricular tags/pits**, and related first/second arch anomalies; laterality is usually **unilateral** but may be bilateral. In a 991-patient cohort: **83% unilateral**, **12% bilateral**; in the same cohort, **53% male / 47% female**. Clinical severity is commonly described with **OMENS / OMENS+** and mandibular grading with **Pruzansky-Kaban**. | HPO: Facial asymmetry; HPO: Microtia; HPO: Mandibular hypoplasia; HPO: Preauricular tag; HPO: Hearing impairment; UBERON: mandible; UBERON: pinna; NCIT: Diagnostic Procedure | (pqac-00000003, pqac-00000011) |
| Extracraniofacial systems with frequencies | Large retrospective multicenter cohort (**n=991**) found extracraniofacial anomalies in **47%** overall. By system: **vertebral 28%**, **circulatory 21%**, **CNS 11%**, **urogenital 11%**, **gastrointestinal 9%**, **respiratory 3%**. Bilateral CFM had higher extracraniofacial anomaly prevalence (**68%**) than unilateral (**44%**). | HPO: Vertebral anomaly; HPO: Congenital heart defect; HPO: Central nervous system abnormality; HPO: Genitourinary abnormality; HPO: Gastrointestinal malformation; HPO: Respiratory system abnormality; UBERON: vertebral column; UBERON: heart; UBERON: kidney; UBERON: brain | (pqac-00000001, pqac-00000003, pqac-00000014, pqac-00000016) |
| Causal genes / susceptibility genes | **Higher-confidence causal gene evidence:** **FOXI3** (Nature Communications 2023; likely pathogenic variants in **21/670 probands = 3.1%**; variant classes included **14 missense, 2 in-frame deletions, 1 frameshift, 1 truncating** across 18 distinct variants; evidence from human genetics + in vitro assays + knock-in mice). **SF3B2** is strongly associated in disease-target resources and prior human genetic literature. **Emerging / candidate genes:** **CHAF1A** (resource-level association), **MYT1**, **EYA3**, **EFTUD2**, **VWA1**, and family-based candidates including **SIX1, PDGFRA, KDR/VEGFR2**. **Susceptibility loci / candidate genes from GWAS:** **ROBO1, GATA3, GBX2, FGF3, NRP2, EDNRB, SHROOM3, SEMA7A, ARID3B, KLF12, EPAS1, PLCD3**. | GO: DNA-binding transcription factor activity; GO: RNA splicing; GO: neural crest cell migration; CL: cranial neural crest cell | (pqac-00000000, pqac-00000004, pqac-00000005, pqac-00000006, pqac-00000007, pqac-00000010, pqac-00000012, pqac-00000015, pqac-00000017, pqac-00000018) |
| Inheritance / penetrance | Most CFM is **sporadic**, but familial forms occur. For **FOXI3**, inheritance can be **autosomal dominant with reduced penetrance** and/or **autosomal recessive**. Reduced penetrance is supported by transmission from apparently unaffected parents and a proposed **modifier haplotype / gene-dosage** model. Family-based OAVS/CFM studies further support **incomplete penetrance** and **variable expressivity**. | HPO: Reduced penetrance; HPO: Variable expressivity | (pqac-00000005, pqac-00000007, pqac-00000008, pqac-00000009, pqac-00000019, pqac-00000020) |
| Developmental mechanism / pathophysiology | Best-supported model is **disturbed development of first/second pharyngeal arch derivatives during the first ~6 weeks of embryogenesis**, involving **cranial neural crest cell migration/differentiation** and likely **vascular patterning / mandibular growth** defects. GWAS candidates are enriched for **embryonic development, organ/system development, and cell migration** pathways. **FOXI3** variants reduce transcriptional activity; NLS variants impair **nuclear entry**, forkhead-domain variants can cause **intranuclear aggregation**. | GO: Neural crest cell migration; GO: embryonic craniofacial morphogenesis; GO: regulation of transcription by RNA polymerase II; GO: angiogenesis; CL: cranial neural crest cell; UBERON: Meckel cartilage; UBERON: pharyngeal arch | (pqac-00000006, pqac-00000012, pqac-00000014, pqac-00000015, pqac-00000018, pqac-00000019) |
| Model-organism evidence | **Knock-in mouse models** of **Foxi3** support causality. Homozygotes showed severe craniofacial phenotypes including **underdeveloped mandible**, **microtia/absent external ear**, **asymmetric skull**, **cleft palate in ~50%**, absent ear bones, and **syngnathia**; heterozygotes showed milder or variable abnormalities. This provides strong experimental recapitulation of human disease mechanisms. | CL: cranial neural crest cell; GO: animal organ morphogenesis; UBERON: mandible; UBERON: palate; HPO analog terms for human mapping: cleft palate, microtia, mandibular hypoplasia | (pqac-00000006, pqac-00000008, pqac-00000011, pqac-00000013) |
| Diagnostics | Diagnosis is primarily **clinical + imaging-based**, using **OMENS/OMENS+** and **Pruzansky-Kaban** classification. Recommended workup includes **physical examination** plus targeted screening for extracraniofacial anomalies: **electrocardiography/echocardiography**, **renal ultrasound**, **spinal radiographs**, and **brain/spine MRI when indicated**. Research and specialty-center phenotyping increasingly use **3D imaging / cone-beam CT** and genomic sequencing. | NCIT: Magnetic Resonance Imaging; NCIT: Echocardiography; NCIT: Ultrasonography; NCIT: Computed Tomography; NCIT: Genetic Testing; UBERON: kidney; UBERON: vertebral column; UBERON: brain | (pqac-00000001, pqac-00000003, pqac-00000016, pqac-00000022, pqac-00000023) |
| Management / real-world implementation | Current care is **multidisciplinary** and predominantly **surgical/reconstructive** plus hearing, speech, dental/orthodontic, and psychosocial support. Active real-world/research implementations include **mandibular distraction osteogenesis** with **CAD/CAM or computer-guided templates**, **fat grafting** with or without **adipose-derived regenerative cells (ADRC)** for soft-tissue augmentation, and regenerative adjuncts such as **bone marrow aspirate concentrate**. Observational registries/natural-history cohorts are also major current applications. | NCIT: Mandibular Distraction Osteogenesis; NCIT: Fat Grafting; NCIT: Reconstructive Surgical Procedure; NCIT: Orthodontic Procedure; NCIT: Speech Therapy; NCIT: Psychosocial Intervention | (pqac-00000021, pqac-00000023, pqac-00000024, pqac-00000025, pqac-00000026, pqac-00000027) |
| Epidemiology | Frequently cited birth prevalence estimate is approximately **1 in 7,500 live births** (from NIH natural-history protocol context). Sex distribution in a large cohort was **53% male / 47% female**. Disease burden spans childhood into adulthood because facial growth, occlusion, hearing, airway, and reconstructive needs evolve over time. | HPO: Congenital onset; HPO: Facial asymmetry | (pqac-00000003, pqac-00000022) |
| Environmental / prenatal risk factors | Evidence supports **multifactorial etiology**. Environmental factors mentioned in human studies/reviews include **maternal obesity**, **periconceptional folic acid use**, and **vasoactive exposures during pregnancy** as studied/implicated risk modifiers, but effect sizes and causal certainty remain less robust than for the strongest recent genetic evidence. | CHEBI term suggestions if curating exposures: folic acid; vasoactive agents | (pqac-00000017) |
| Evidence gaps / unavailable or limited data | No validated **disease-specific blood/urine biomarkers** were identified in retrieved evidence. No established **pharmacotherapy**, **gene therapy**, or routine **omics-based diagnostic biomarker** is in clinical use. Protective genetic/environmental factors are poorly defined. Population-specific prevalence, mortality, life expectancy, penetrance estimates for most genes, and standardized treatment-response rates remain limited. Some recent 2023–2024 surveys/reviews were not fully retrievable in this session, so large parts of current practice still rely on older cohort data plus ongoing trials/registries. | NCIT: Biomarker; NCIT: Gene Therapy; NCIT: Clinical Trial | (pqac-00000000, pqac-00000021, pqac-00000022) |


*Table: This table condenses the main knowledge-base annotations for craniofacial microsomia, covering identity, phenotype, genetics, mechanisms, diagnostics, management, and gaps. It is useful as a compact structured summary for ontology mapping and evidence-backed curation.*